| Metric | Q3-26 | Q3-25 |
|---|---|---|
| Revenue | 2.82 | 0.50 |
| Pretax Income | -2.06 | -1.62 |
| Net Income | 50.79 | -1.54 |
| Diluted EPS | 1.24 | -0.04 |
- Net Income YoY
- +3,398.2%
Key highlights
- Net income reached $50.79 million, representing a 3,398.2% increase over the previous year
- Quarterly revenue rose to $2.82 million, up from $0.50 million in Q3 2025
- Diluted earnings per share stood at $1.24, compared to a loss of $0.04 per share in the prior-year period
- A one-time gain of $53.7 million was recorded from the sale of subsidiary interests and deconsolidation
- Operating losses from continuing operations totaled $2.1 million for the quarter
How the Period Went
BeyondSpring reported a significant shift in its bottom line for the third quarter of 2026, recording net income of $50.79 million, compared to a net loss of $1.54 million in the same period last year. This represents a year-over-year increase of 3,398.2%. While the company's revenue grew to $2.82 million from $0.50 million in Q3 2025, the primary driver for the net profit was a one-time $53.7 million gain resulting from the sale of subsidiary interests and the deconsolidation of discontinued operations. Despite the top-line growth, the company's pretax income remained negative at $2.06 million, reflecting ongoing operational expenses during its development phase.
Margins and Profitability
The disconnect between operating performance and net profit defines the current period. BeyondSpring continues to face operating losses from continuing operations, which totaled $2.1 million for the quarter. These losses highlight the capital-intensive nature of its current stage, as the company remains largely in development with limited recurring revenue. The $53.7 million exceptional gain from the subsidiary sale transformed a $2.06 million pretax loss into a diluted earnings per share of $1.24, compared to a loss per share of $0.04 in the prior year. This strategic divestiture provided a substantial liquidity boost but does not yet represent sustainable profitability from core biotechnology activities.
Business Overview
BeyondSpring Inc. is a clinical-stage biotechnology company focused on the development and commercialization of innovative cancer therapies. Based in the United States, the company targets unmet medical needs in the healthcare sector, specifically within the oncology market. Its primary focus involves advancing its pipeline of small molecule assets, including its lead candidate designed to treat chemotherapy-induced neutropenia and various solid tumors. The company's business model relies on clinical advancement and strategic partnerships or divestitures, such as the deconsolidation event noted this quarter, to fund its ongoing research and development initiatives while it lacks a fully commercialized product portfolio.
Financial Context
The Q3 2026 results arrive as BeyondSpring navigates a challenging market environment, with its stock price recently trading at $0.6012. With a market capitalization of approximately $24.72 million, the company is categorized as a micro-cap entity within the biotechnology industry. The stock has experienced a 19.0% decline over the past quarter, although it showed a modest 2.39% gain over the last month. Technical indicators show a Relative Strength Index of 48.8, suggesting the stock is currently in neutral territory. The substantial net income figure this period stands in sharp contrast to the company's longer-term revenue trend, which remains modest relative to its development-stage operating costs.
Down 3.7% since our story on 16 Nov: $0.60 when we broke it → $0.58 at the close on 16 Nov. Daily closing prices. Source: Yahoo Finance.
Show the prices
| 19 Oct | $0.51 |
|---|---|
| 20 Oct | $0.52 |
| 21 Oct | $0.50 |
| 22 Oct | $0.45 |
| 23 Oct | $0.43 |
| 26 Oct | $0.46 |
| 27 Oct | $0.46 |
| 28 Oct | $0.53 |
| 29 Oct | $0.52 |
| 30 Oct | $0.64 |
| 2 Nov | $0.81 |
| 3 Nov | $0.62 |
| 4 Nov | $0.68 |
| 5 Nov | $0.63 |
| 6 Nov | $0.63 |
| 9 Nov | $0.62 |
| 10 Nov | $0.58 |
| 11 Nov | $0.64 |
| 12 Nov | $0.60 |
| 13 Nov | $0.60 |
| 16 Nov | $0.58 |
Industry Landscape
The biotechnology sector is currently defined by a bifurcation between established commercial-stage firms and clinical-stage companies like BeyondSpring that rely on external financing or strategic asset sales. Demand for novel oncology treatments remains high, but investors are increasingly focused on path-to-profitability and cash runways. Peers in the micro-cap biotech space frequently utilize subsidiary deconsolidations or licensing agreements to offset high research and development burn rates. BeyondSpring’s shift toward a positive net income through a divestiture aligns with broader industry trends where smaller firms monetize specific pipeline assets or subsidiaries to sustain their primary clinical objectives without relying solely on dilutive equity financing.
| Share price | $0.60 |
|---|---|
| Market cap | $25M |
| 1-month price change | +2.39% |
| Sector | HealthcareBiotechnology |
Reference market data from a third-party provider, as of the story. Not a valuation or a recommendation.
SEC filing by BeyondSpring Inc. announcing third quarter 2026 financial results.
Track BeyondSpring Inc. live
Get the next BeyondSpring Inc. SEC filing seconds after it lands.



